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Abstract
Aims: Selective use of DES only in patients at higher risk of MACE is common practice, particularly in 
healthcare systems with a large premium payable for DES. We aimed to identify subgroups of patients 
in which the use of BMS in primary percutaneous coronary intervention (PPCI) for STEMI can still be 
justified.
Methods and results: We performed a patient-level pooled analysis of COMFORTABLE AMI and 
EXAMINATION comparing contemporary DES with BMS in PPCI. A risk score was applied using three 
parameters: lesion length >15 mm, vessel size <3 mm, and diabetes mellitus. Individual data were avail-
able for 2,655 patients. The incidence of MACE at one year was incrementally higher in patients with risk 
scores of 1 or 2/3. MACE rates were lower in patients with a risk score 0 or 1 who were treated with DES 
(p=0.0073 and p=0.008). No difference in death or reinfarction was seen between DES and BMS in any 
group. There was a significant reduction in TLR with DES in all three groups.
Conclusions: A score comprising vessel size, lesion length, and diabetes did not identify patients at low 
risk with equivalent or better results from BMS use. The results suggest that the practice of only selective 
use of DES in primary PCI should be discouraged.
KEYWORDS
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Introduction
Drug-eluting stents (DES) have been shown to reduce the risk of 
restenosis and related events when compared to bare metal stents 
(BMS)1-5. The benefit over BMS is marked in some patient sub-
groups and lesion subsets and is less pronounced or absent in oth-
ers6-11. Use of multiple stents, vessel diameter and diabetes have 
long been identified as predictors of restenosis after stent implan-
tation12. In 2003, the then National Institute of Clinical Excellence 
(NICE) in the United Kingdom issued guidance to use DES over 
BMS selectively in lesions longer than 15 mm and vessel diame-
ters <3 mm. The recommendation was based on cost-effectiveness 
analyses of available data, was confirmed in a revision in 200813, 
and has not been revised since. Selective use of DES has become 
common practice, particularly in healthcare systems with limited 
resources. Often, additional patient factors such as the presence of 
diabetes and the mode of presentation are taken into account when 
choosing between DES and BMS14-16.
In primary percutaneous coronary intervention (PPCI) for acute 
ST-elevation myocardial infarction, first-generation DES have shown 
ambiguous results compared to BMS16-22. In the first year following 
implantation a reduced rate of TLR was documented; however, late 
stent thrombosis was seen more frequently in the following years and, 
overall, there was no benefit with a strategy of general use of DES23.
More recent results with newer-generation DES suggest a reduc-
tion in TLR, as well as reduced stent thrombosis, when DES are 
used in the treatment of STEMI. The COMFORTABLE AMI 
and EXAMINATION trials both reported improved outcomes in 
PPCI24,25. However, it remains unclear whether all patients present-
ing with STEMI should be treated with DES or whether differen-
tial use of DES and BMS can be justified.
It remains common practice to use DES selectively. In the 
recently published large-scale trials TASTE26 and TOTAL27, DES 
were used in less than half of the cases (47.5% and 45%). Given 
the large number of PPCI performed worldwide, the selective use 
of DES has an important cost impact.
We postulated that we would be able to identify patient sub-
groups at low risk of restenosis and MACE, in which DES would 
not have a clinically relevant benefit over BMS in PPCI.
Editorial, see page 1566
Methods
Both COMFORTABLE AMI and EXAMINATION have been 
described in detail28,29.
Briefly, the multicentre COMFORTABLE AMI trial 
(NCT00962416) randomly assigned 1,161 patients to treatment 
with biolimus-eluting stents with biodegradable polymer and bare 
metal stents of otherwise identical design at 11 international sites. 
The primary endpoint was a composite of cardiac death, target 
vessel MI and target lesion revascularisation at one year.
The EXAMINATION trial (NCT00828087) was a multicentre, 
prospective, randomised, all-comer, controlled trial carried out in 12 
medical centres in three countries. Patients with STEMI up to 48 
hrs after the onset of symptoms requiring emergent percutaneous 
coronary intervention were randomly assigned (ratio 1:1) to receive 
an everolimus-eluting stent (EES) or a BMS. The primary endpoint 
was the patient-oriented combined endpoint of all-cause death, any 
recurrent myocardial infarction, and any revascularisation at one 
year, and was analysed by intention to treat. A total of 1,498 patients 
were randomly assigned to receive EES (n=751) or BMS (n=747).
The two trials had different primary endpoints. We used indi-
vidually pooled data of adjudicated events, so we could align the 
events across the two studies.
Data set
Individual patient data were available for the COMFORTABLE 
and EXAMINATION trials.
Three risk criteria were defined based on the recommendations 
of NICE and previous analyses for differential benefits of DES over 
BMS12: 1) small target vessel diameter (<3.0 mm), 2) long lesion length 
(>15 mm) (for this, the maximum stent diameter at implantation and 
a stent length of ≥20 mm were used), 3) presence of diabetes mellitus.
The patients were then grouped according to the risk score: 0 
(absence of the above risk factors, i.e., patients without diabetes, 
short lesion and large target vessel), 1 (presence of one risk fac-
tor), 2 (presence of two or more risk factors)30. The different out-
comes in patients receiving either BMS or a drug-eluting stent 
(BES or EES) were analysed. Patients were stratified according to 
the randomised stent, i.e., by intention-to-treat.
Statistical analyses
Continuous data are presented as means (±SD, p-values from 
ANOVAs) and categorical data as counts (%, p-values from logistic 
regressions). Individual pooled analyses were used to assess differ-
ences in clinical outcomes comparing DES vs. BMS (intention-to-
treat), within each of the three risk score groups, for the pre-specified 
device-oriented composite endpoint of cardiac death, target vessel 
infarction and clinically indicated target lesion revascularisation 
(MACE) at one year, and for the pre-specified endpoints of all-cause 
death, any infarction, clinically indicated target lesion revascularisa-
tion and definite stent thrombosis at one year. Cox’s regressions per 
endpoint, per risk group and per trial comparing DES vs. BMS for 
time-to-first event were used to derive effect sizes (stratified by trial 
when the two trials were pooled). Individual pooled Cox’s regressions 
were used to assess a linear trend over the risk groups comparing the 
randomised stents, again per endpoint, stratified per trial. Kaplan-
Meier curves are based on the pooled individual data. As a sensitivity 
analysis, meta-analyses and meta-regressions were performed, using 
a continuity correction of 0.5 in case of zero events (Online Figure 1, 
Online Figure 2). A two-sided p-value <0.05 was considered as statis-
tically significant. Statistical analysis was performed using Stata soft-
ware, version 12.1 (Stata Corp., College Station, TX, USA). 
Results
Individual data were available for 2,655 patients. The baseline 
characteristics are summarised in Table 1. The majority had one 
risk factor for adverse outcomes.
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Selective use of DES in primary angioplasty
The groups with a risk score of 1 or more showed a significantly 
higher incidence of diabetes, hypercholesterolaemia and hyperten-
sion (p<0.01), therefore identifying a generally higher risk popula-
tion for cardiovascular events.
The group with a risk score of 0 showed significantly shorter 
lesion length, larger stent size used, and higher use of direct stent-
ing techniques (all p<0.001). On average in this group one stent 
was used for one lesion treated.
The pharmacologic treatment in both trials was at the dis-
cretion of the operator. In patients with a risk score of 0, more 
GP IIb/IIIa inhibitors were used (p<0.001) and a higher use of 
unfractionated heparin was reported (p=0.02). The details are 
illustrated in Table 2. Online Table 1-Online Table 4 are sup-
plied to show the data sets of Table 1 and Table 2 separately for 
the two trials.
The incidence of MACE at one year was incrementally higher in 
patients with risk scores of 1 or 2 and 3. In COMFORTABLE AMI, 
the patients with risk scores of 0 or 1 treated with DES had a signi-
ficantly lower MACE rate compared with patients treated with BMS 
(p=0.0009 for risk score 0 and p=0.035 for risk score 1).
Table 1. Baseline and procedural characteristics.
Risk score
None One Two or three p-values
DES
N=324
BMS
N=350
DES
N=730
BMS
N=709
DES
N=272
BMS
N=270
Score Stent
Score x stent 
interactiona
Age (years) 58.61±11.46 58.85±12.23 60.45±12.08 61.35±12.22 64.21±11.50 63.30±12.12 <0.001 0.50 0.32
Male gender, n (%) 270 (83.33) 284 (81.14) 619 (84.79) 568 (80.11) 208 (76.47) 213 (78.89) 0.06 0.09 0.17
Body mass index (kg/m²) 27.07±3.79 27.40±4.04 27.30±4.05 27.06±3.83 27.34±4.53 27.93±4.09 0.09 0.66 0.08
Cardiovascular risk factors
Diabetes mellitus, n (%) 0 (0.00) 0 (0.00) 60 (8.22) 61 (8.60) 161 (59.41) 150 (55.56) <0.001 0.58 0.72
Hypertension, n (%) 133 (41.05) 147 (42.00) 326 (44.66) 330 (46.54) 167 (61.62) 166 (61.48) <0.001 0.56 0.92
Hypercholesterolaemia, n (%) 155 (47.84) 159 (45.69) 369 (50.76) 330 (46.68) 154 (56.83) 140 (51.85) 0.01 0.05 0.87
Current smoker, n (%) 174 (54.04) 197 (56.45) 349 (48.01) 366 (51.77) 121 (44.98) 124 (46.44) <0.001 0.12 0.89
Family history, n (%) 89 (28.62) 73 (21.99) 174 (24.82) 163 (24.11) 64 (25.20) 62 (24.51) 0.87 0.20 0.33
Previous MI, n (%) 11 (3.40) 14 (4.00) 40 (5.48) 44 (6.21) 13 (4.80) 21 (7.78) 0.04 0.20 0.66
Previous PCl, n (%) 9 (2.78) 8 (2.29) 26 (3.56) 36 (5.08) 13 (4.80) 15 (5.56) 0.02 0.29 0.58
Previous CABG, n (%) 1 (0.31) 5 (1.43) 7 (0.96) 6 (0.85) 5 (1.85) 0 (0.00) 0.95 0.68 0.40
Clinical presentation
Primary PCI (<12 hrs), n (%) 284 (87.65) 299 (85.43) 645 (88.36) 625 (88.15) 231 (84.93) 235 (87.04) 0.74 0.42 0.62
Killip class II, III or IV, n (%) 22 (6.81) 24 (6.88) 67 (9.19) 64 (9.05) 31 (11.40) 25 (9.26) 0.03 0.62 0.79
LV ejection fraction (%) 50.48±11.21 50.31±9.61 50.04±10.80 50.25±10.18 49.23±11.06 50.72±9.75 0.82 0.40 0.44
Site of infarct-related artery, n (%) 0.99 0.84 0.92
Left main 1 (0.31) 1 (0.29) 2 (0.27) 2 (0.28) 0 (0.00) 0 (0.00)
Left anterior descending 142 (43.83) 155 (44.41) 278 (38.08) 269 (37.94) 129 (47.43) 111 (41.11)
Left circumflex 47 (14.51) 49 (14.04) 99 (13.56) 97 (13.68) 38 (13.97) 51 (18.89)
Right circumflex 134 (41.36) 142 (40.69) 349 (47.81) 338 (47.67) 103 (37.87) 108 (40.00)
Saphenous vein graft 0 (0.00) 2 (0.57) 2 (0.27) 3 (0.42) 2 (0.74) 0 (0.00)
Angiographic and procedural characteristics
TIMI flow 0 to 2 before PCI, n (%) 245 (76.09) 282 (81.74) 624 (85.71) 588 (83.29) 220 (80.88) 229 (85.13) 0.04 0.55 0.05
Thrombus aspiration, n (%) 218 (67.28) 246 (70.49) 468 (64.11) 462 (65.16) 159 (58.46) 147 (54.44) <0.001 0.72 0.41
Multivessel treatment, n (%) 2 (0.62) 2 (0.57) 49 (6.71) 35 (4.94) 9 (3.31) 14 (5.19) <0.001 0.38 0.27
Treatment of LAD, n (%) 143 (44.14) 156 (44.70) 292 (40.00) 279 (39.35) 131 (48.16) 112 (41.48) 0.95 0.44 0.40
Lesions and stenting
No. of lesions treated 1.02±0.15 1.01±0.14 1.23±0.50 1.24±0.51 1.21±0.45 1.23±0.46 <0.001 0.91 0.96
Total stent length (mm) 16.25±2.57 16.06±2.88 31.66±15.07 30.68±15.18 33.14±14.60 33.89±14.26 <0.001 0.24 0.40
Maximum stent diameter (mm) 3.37±0.34 3.42±1.38 3.28±0.45 3.28±0.59 2.96±0.49 2.94±0.47 <0.001 0.80 0.57
No. of stents implanted 1.00±0.06 0.99±0.11 1.57±0.74 1.54±0.83 1.60±0.77 1.68±0.80 <0.001 0.68 0.27
Direct stenting, n (%) 196 (61.44) 217 (64.97) 380 (52.63) 355 (50.35) 110 (40.44) 91 (33.83) <0.001 0.42 0.19
Overlapping stents, n (%) 0 (0.00) 1 (0.29) 247 (33.84) 211 (29.76) 100 (36.76) 115 (42.75) <0.001 0.38 0.11
Depicted are counts (%) or means±SD, p-values from ANOVAs or logistic regressions (risk score group linear, randomised stent). ap-value interaction risk group (linear) x stent from the 
full-factorial models.
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In EXAMINATION, the rate of MACE was lower in patients 
treated with DES in all three groups; however, this difference was 
not statistically significant. The pooled analysis showed signi-
ficantly lower MACE rates in patients with risk score 0 or 1 
who were treated with DES (p=0.0073 and p=0.008). In patients 
with a risk score of 2 or 3, deemed at highest risk for resteno-
sis and adverse cardiac events, the difference in MACE at one 
year between the patients treated with DES or BMS did not reach 
statistical significance. Details are shown in Table 3. Figure 1 pro-
vides Kaplan-Meier curves for MACE and revascularisation.
The rate of death was higher with a risk score of 1 or more; 
however, no difference was seen between DES and BMS in any 
of the groups.
The rate of reinfarction was higher with a risk score of one 
or more, but not different between DES and BMS in any of the 
groups.
Table 2. Medication during procedure, at discharge and follow-up.
Risk score
None One Two or three p-values
DES BMS DES BMS DES BMS Score Stent Score × stent interactiona
During primary PCI n=324 n=350 n=730 n=708 n=272 n=270
Aspirin*, n (%) 311 (95.99) 335 (95.71) 692 (94.79) 672 (94.92) 262 (96.32) 264 (97.78) 0.46 0.77 0.59
Clopidogrel*, n (%) 291 (89.81) 309 (88.29) 648 (88.77) 624 (88.01) 244 (89.71) 244 (90.37) 0.68 0.55 0.79
Prasugrel*, n (%) 53 (16.36) 52 (14.86) 140 (19.18) 141 (19.89) 38 (13.97) 45 (16.67) 0.93 0.75 0.59
Any DAPT*, n (%) 307 (94.75) 326 (93.14) 687 (94.11) 665 (93.79) 255 (93.75) 259 (95.93) 0.16 0.97 0.07
UF heparin, n (%) 282 (87.04) 298 (85.14) 607 (83.15) 596 (84.06) 220 (80.88) 219 (81.11) 0.02 0.94 0.70
LMW heparin, n (%) 21 (6.48) 20 (5.71) 40 (5.48) 45 (6.35) 20 (7.35) 25 (9.26) 0.14 0.49 0.66
Bivalirudin, n (%) 28 (8.64) 32 (9.14) 70 (9.59) 68 (9.59) 25 (9.19) 23 (8.52) 0.98 0.99 0.94
GP IIb/IIIa antagonists, n (%) 154 (47.53) 156 (44.57) 309 (42.33) 292 (41.18) 103 (37.87) 97 (35.93) 0.001 0.38 0.93
At discharge n=323 n=347 n=725 n=704 n=268 n=269
Aspirin, n (%) 323 (100.00) 345 (99.42) 719 (99.17) 701 (99.57) 267 (99.63) 267 (99.26) 0.50 1.00 0.63
Any DAPT, n (%) 323 (100.00) 343 (98.85) 718 (99.03) 700 (99.57) 265 (99.25) 267 (99.26) 0.75 0.99 0.80
At 30 days n=308 n=332 n=689 n=671 n=248 n=255
Aspirin, n (%) 307 (99.68) 327 (98.49) 679 (98.55) 666 (99.25) 244 (98.39) 254 (99.61) 0.90 0.42 0.12
Any DAPT, n (%) 307 (99.68) 324 (97.59) 675 (97.83) 660 (98.51) 241 (97.18) 253 (99.22) 0.59 0.62 0.04
At one year n=290 n=322 n=682 n=645 n=246 n=249
Aspirin, n (%) 283 (97.59) 314 (97.52) 667 (97.80) 630 (97.67) 237 (96.34) 241 (96.79) 0.26 0.89 0.91
Any DAPT, n (%) 271 (93.45) 282 (87.58) 640 (93.84) 573 (88.84) 227 (92.28) 218 (87.55) 0.86 0.00 0.91
Depicted are counts (%) or means±SD, p-values from ANOVAs or logistic regressions (NICE group linear, randomised stent). Missing data assumed no medication taken for: None/DES aspirin 
to DAPT during PCI and aspirin at 1 year; One/DES aspirin at 30 days; One/BMS aspirin during PCI and DAPT at discharge and follow-up 30 days; Two or three/DES DAPT at discharge; n=1 
missing for each case respectively. ap-value interaction NICE risk group (linear) × stent from the full-factorial models. *Loading dosage or already on for ASA, clopidogrel and prasugrel. DAPT 
was ASA with clopidogrel in EXAMINATION, and ASA with clopidogrel or prasugrel in COMFORTABLE. DAPT: dual antiplatelet therapy; GP: glycoprotein; LMW: low molecular weight; 
UF: unfractionated
Table 3. MACE at one year according to risk score.
Study Risk score
DES BMS
Hazard ratio (95% CI) p-value Interactiona
n events (%) n events (%)
COMFORTABLE Two or three 107 11 (10.3) 102 12 (11.8) 0.867 (0.383-1.966) 0.7332 0.013
One 320 13 (4.1) 319 26 (8.2) 0.489 (0.251-0.952) 0.0353
None 148 0 (0.0) 161 11 (6.8)  0.047 (0.003-0.791)b 0.0009
EXAMINATION Two or three 165 12 (7.3) 168 17 (10.1) 0.708 (0.338-1.482) 0.3597 0.736
One 410 23 (5.6) 390 34 (8.7) 0.633 (0.373-1.075) 0.0906
None 176 6 (3.4) 189 11 (5.8) 0.576 (0.213-1.558) 0.2774
Individual 
pooled data
Two or three 272 23 (8.5) 270 29 (10.7) 0.775 (0.448-1.340) 0.3618 0.075
One 730 36 (4.9) 709 60 (8.5) 0.572 (0.378-0.864) 0.0080
None 324 6 (1.9) 350 22 (6.3) 0.290 (0.118-0.716) 0.0073
Shown are separate Cox’s regressions per study and risk group (stratified per study for individual pooled data) with p-value for randomised stent effect. 
ap-value for interaction risk group (linear) × stent in a Cox’s regression across all three risk groups (stratified per study for individual pooled data). bRisk 
ratio (95% CI) after continuity correction.
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The rate of clinically indicated target lesion revascularisation 
(TLR) was lower in patients with a score of 0. There was a sig-
nificant reduction in TLR with DES in all three risk score groups. 
Patients without diabetes, large vessel diameters and short lesions 
(risk score 0) still derived a benefit from a lower TLR when treated 
with DES (0.3% vs. 3.7%, p=0.0161). Stent thrombosis was lower 
with the use of DES in all risk score groups. Table 4 gives details 
of clinical outcomes according to treatment and risk score.
A further analysis looking at the three risk criteria individually 
in relation to clinical endpoints is illustrated in Figure 2. Individual 
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Number at risk
None 324 315 311 311 311 310 307
One 730 699 695 694 689 685 677
Two or three 272 256 255 253 253 251 244
Number at risk
None 324 317 315 315 315 315 312
One 730 710 708 707 703 700 691
Two or three 272 261 261 259 259 258 253
Number at risk
None 350 336 333 330 328 326 321
One 709 666 660 656 648 643 631
Two or three 270 256 249 242 238 237 235
Number at risk
None 350 340 337 334 332 330 326
One 709 682 677 674 666 661 650
Two or three 270 258 251 245 241 240 238
Figure 1. Major adverse cardiac events (MACE) and clinically driven target lesion revascularisation (TLR) at one year for the three risk score 
groups (0: grey, 1: pink, 2/3: red) and separately for drug-eluting stents (DES) and bare metal stents (BMS) used for primary angioplasty.
Table 4. Individual pooled analysis of clinical outcomes at one year comparing DES vs. BMS in the three risk score groups.
Outcome Risk score
DES BMS
Hazard ratio (95% CI) p-value p-value 
interactionan events (%) n events (%)
Death Two or three 272 17 (6.3) 270 9 (3.3) 1.886 (0.840-4.230) 0.1240 0.033
One 730 21 (2.9) 709 28 (3.9) 0.724 (0.411-1.275) 0.2637
None 324 6 (1.9) 350 12 (3.4) 0.541 (0.203-1.440) 0.2186
Stent 
thrombosis
Two or three 272 3 (1.1) 270 6 (2.2) 0.489 (0.122-1.956) 0.3120 0.518
One 730 5 (0.7) 709 15 (2.1) 0.319 (0.116-0.879) 0.0271
None 324 1 (0.3) 350 5 (1.4) 0.216 (0.025-1.848) 0.1617
Reinfarction Two or three 272 7 (2.6) 270 12 (4.4) 0.570 (0.225-1.449) 0.2377 0.955
One 730 11 (1.5) 709 18 (2.5) 0.588 (0.278-1.246) 0.1658
None 324 3 (0.9) 350 6 (1.7) 0.540 (0.135-2.159) 0.3835
TLR Two or three 272 7 (2.6) 270 24 (8.9) 0.282 (0.121-0.654) 0.0032 0.555
One 730 14 (1.9) 709 31 (4.4) 0.433 (0.230-0.813) 0.0093
None 324 1 (0.3) 350 13 (3.7) 0.082 (0.011-0.629) 0.0161
aP-value for NICE risk group (linear) × stent in a Cox’s Regression across all three NICE risk groups (stratified per study for Individual-Pooled Data).
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risk factors did not predict a differential benefit of DES with respect 
to a reduction of TLR. The reduction in clinically indicated TLR 
was significant across all patient groups, whether individual risk 
factors (diabetes, long lesion, small vessel) were present or not.
The numbers needed to treat (NNT) in order to avoid one 
MACE with the use of DES were 21 in patients with a risk score 
of 0, 28 in patients with a risk score of 1, and 48 in patients with 
a risk score of 2 or 3.
Numbers needed-to-treat with a DES to avoid one TLR were 30 
in patients with a risk score of 0, 41 in patients with a risk score 
of 1 and 16 in patients with a risk score of 2 or 3.
Discussion
The major finding of this pooled analysis is that, with the use of 
contemporary drug-eluting stents in primary PCI, a clinical bene-
fit over bare metal stents was seen irrespective of the presence of 
Outcome Events/patients Events/patients Hazard ratio p-valuea p-value
DES BMS (95% Cl) trendb
MACE
Diabetes - yes 21/221 21/211 0.959 (0.524-1.758) 0.893 0.062
Diabetes - no 44/1,105 90/1,118 0.485 (0.339-0.696) <0.001
Small vessel - yes 12/248 25/265 0.501 (0.252-0.997) 0.049 0.666
Small vessel - no 53/1,078 86/1,064 0.598 (0.425-0.843) 0.003
Long lesion - yes 51/834 74/800 0.649 (0.454-0.927) 0.017 0.183
Long lesion - no 14/492 37/529 0.398 (0.215-0.736) 0.003
Death
Diabetes - yes 17/221 10/211 1.679 (0.768-3.670) 0.194 0.067
Diabetes - no 27/1,105 39/1,118 0.698 (0.427-1.140) 0.150
Small vessel - yes 7/248 6/265 1.240 (0.417-3.690) 0.699 0.516
Small vessel - no 37/1,078 43/1,064 0.847 (0.546-1.314) 0.458
Long lesion - yes 33/834 31/800 1.018 (0.624-1.663) 0.942 0.340
Long lesion - no 11/492 18/529 0.656 (0.310-1.390) 0.272
Reinfarction
Diabetes - yes 5/221 10/211 0.494 (0.169-1.448) 0.199 0.720
Diabetes - no 16/1,105 26/1,118 0.617 (0.331-1.150) 0.128
Small vessel - yes 4/248 9/265 0.465 (0.143-1.511) 0.203 0.677
Small vessel - no 17/1,078 27/1,064 0.621 (0.338-1.139) 0.124
Long lesion - yes 16/834 25/800 0.606 (0.324-1.136) 0.118 0.738
Long lesion - no 5/492 11/529 0.486 (0.169-1.398) 0.181
TLR (clinically indicated)
Diabetes - yes 5/221 14/211 0.338 (0.121-0.938) 0.037 0.903
Diabetes - no 17/1,105 54/1,118 0.313 (0.182-0.540) <0.001
Small vessel - yes 5/248 19/265 0.276 (0.103-0.740) 0.010 0.734
Small vessel - no 17/1,078 49/1,064 0.338 (0.195-0.586) <0.001
Long lesion - yes 18/834 48/800 0.352 (0.205-0.605) <0.001 0.414
Long lesion - no 4/492 20/529 0.212 (0.072-0.620) 0.005
Definite stent thrombosis
Diabetes - yes 3/221 4/211 0.747 (0.167-3.346) 0.703 0.274
Diabetes - no 6/1,105 22/1,118 0.274 (0.111-0.677) 0.005
Small vessel - yes 1/248 4/265 0.260 (0.029-2.323) 0.228 0.801
Small vessel - no 8/1,078 22/1,064 0.357 (0.159-0.803) 0.013
Long lesion - yes 7/834 19/800 0.351 (0.148-0.836) 0.018 0.886
Long lesion - no 2/492 7/529 0.310 (0.064-1.490) 0.144
.05 .1 .25 .5 1 2 4
Figure 2. Individual pooled analyses of clinical outcomes in the presence of individual risk factors (lesion length, vessel size and diabetes) for 
DES vs. BMS use. a p-values random effects using separate Cox’s regressions per outcome and per presence or absence of the risk factor 
(stratified by study). b p-values for the interaction between stent type and presence/absence of risk factor from the full-factorial Cox’s 
regression (stratified by study).
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risk criteria for restenosis. The use of bare metal stents in patients 
without anatomical or clinical risk factors (short lesions, large ves-
sel and absence of diabetes) was still associated with a higher rate 
of repeat revascularisation.
The risk of adverse events, especially revascularisation, was 
higher in patients with diabetes, long lesions and small arteries. 
The number needed-to-treat to avoid one revascularisation with 
a DES vs. BMS was smallest when two or more risk factors were 
present. Contrary to the original hypothesis, the number needed-
to-treat in patients without any of these criteria was still sufficient 
to justify the use of DES.
This is in contrast to published findings in patients receiving 
stents for the treatment of stable angina and a previous similar 
assessment in a propensity-matched analysis covering all percuta-
neous interventions in Ontario30. In this study with a similar risk 
score approach applied to the analysis, DES were associated with 
significant reductions in the rate of target vessel revascularisation 
among patients with two or three risk factors for restenosis (i.e., 
presence of diabetes, small vessels [<3 mm in diameter], and long 
lesions [>or=20 mm]) but not among lower-risk patients. Only 
a small proportion of these patients presented with STEMI.
NICE originally recommended the selective use of DES over 
BMS in lesion subsets with small target vessels and long target 
lesions, based on the analysis of early RCT for paclitaxel-eluting 
stents (TAXUS™; Boston Scientific, Marlborough, MA, USA) and 
sirolimus-eluting stents (CYPHER®; Cordis, Johnson & Johnson, 
Miami Lakes, FL, USA). The revised guidance from 2008, again 
a health economic analysis and recommendation, was based on 
a total of 17 RCT including second-generation DES. None of the 
trials included patients presenting with STEMI and these patients 
were excluded from the guidance.
Limited data are available in the context of primary PCI. In 
HORIZONS-AMI31, patients presenting with STEMI were ran-
domised to receive either a PES or a BMS (3:1 randomisation). 
After three years, patients who received a PES had lower rates of 
ischaemia-driven TLR (9.4% vs. 15.1%; p<0.0001), with no sig-
nificant differences in the rates of death, reinfarction, stroke or 
stent thrombosis22. A later analysis showed that insulin-treated dia-
betes mellitus (hazard ratio [HR]: 3.12), reference vessel diameter 
<3.0 mm (HR: 2.89), and lesion length ≥30 mm (HR: 2.49) were 
independent predictors of 12-month TLR after BMS10. In patients 
with two or three of these baseline risk factors, PES use markedly 
reduced 12-month TLR in comparison with BMS (19.8% vs. 8.1%, 
p=0.003). In patients with one of these risk factors, the 12-month 
rates of TLR were modestly reduced by PES (7.3% vs. 4.3%, 
p=0.02). The 12-month TLR rates were low and similar for both 
stents in patients with zero risk factors (3.3% vs. 3.2%, p=0.93).
In comparison with the presented studies, MACE rates in 
HORIZONS-AMI were in a similar range. The 12-month 
outcomes in the BMS arms were 3.5% for death in both 
COMFORTABLE AMI and HORIZONS-AMI, rates of reinfarc-
tion were 3.7% and 4.5%, and for ischaemia-driven TLR 5.7% 
and 7.4%, respectively.
A difference in outcome was noted in patients with no risk fac-
tors; the TLR rate in our pooled analysis demonstrated only one 
event (0.3%) in the DES group. This may reflect the advantage of 
a newer-generation DES in comparison with PES, and explains 
why in this study the benefit of DES was seen in the lowest risk 
patients as well.
Interestingly, in this cohort of patients undergoing primary PCI, 
none of the individual risk factors chosen for the score predicted 
an increased benefit of DES over BMS. The reduction in TLR was 
similar, whether diabetes, small vessel size or long lesion length 
was present or not.
The combination of more than one risk factor did increase the 
absolute risk of an event. However, the increase in the TLR rate 
was much less steep in the DES group than in the BMS group. In 
the highest risk group with two or more risk factors, the TLR rate 
with BMS was 8.9% compared to 2.6% in the DES group.
The NNT to avoid one MACE was higher in the higher-
risk score group. This is a surprising finding as we would have 
expected a larger benefit in patients with more risk factors. This 
finding points towards a weakness of the chosen risk criteria to 
identify benefits of DES. The patient cohort with high risk scores 
may have had additional patient-related factors that reduced the 
effect of the TLR rate on the overall MACE.
When looking at cost-effectiveness, the price difference between 
DES and BMS has to be taken into account32. With clinical data 
suggesting a benefit in all subgroups of patients, selective rather 
than general use of contemporary DES for PPCI can only be justi-
fied in healthcare systems with a very large premium payable for 
the use of DES.
Limitations
The risk criteria of length and vessel diameter in this study are 
derived from the diameter and lengths of the stents used, rather 
than QCA analysis of the target lesion and vessel. The assess-
ment of length and diameter may be more difficult in the setting of 
STEMI than in elective situations, and may lead to overestimation 
of length of the lesion and underestimation of true vessel size. The 
EXAMINATION trial included patients presenting >24 hours fol-
lowing symptom onset, and patients undergoing rescue angioplasty 
for failed thrombolysis. Hence, the studied population is hetero-
geneous and the effect of late presentation and increased infarct 
sizes may have diminished the clinical effect of DES over BMS. 
Neither trial included angiographic follow-up; consequently, the 
reported outcomes are clinically driven and may not reflect the 
angiographic incidence of in-stent restenosis. The two trials used 
DES with absorbable and permanent polymers. We cannot exclude 
different results with these individual devices.
Conclusions
In this large cohort of patients undergoing primary PCI for acute 
ST-elevation myocardial infarction, the use of drug-eluting stents 
showed a clinical benefit over bare metal stents in all patient 
groups. Contrary to common practice, selection of BMS for 
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patients without risk factors (long lesions, small vessels, diabe-
tes) would not translate into equivalent outcomes. The selective 
use of DES should be discouraged.
Impact on daily practice
The use of contemporary drug-eluting stents (DES) for primary 
percutaneous coronary intervention (PPCI) shows a clinical 
benefit over bare metal stents in all patients. Routine practice 
should adopt the universal use of contemporary DES.
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Online Table 1. Baseline and procedural characteristics of COMFORTABLE patients.
NICE risk factors
None One Two or three p-values
DES
N=148
BMS
N=161
DES
N=320
BMS
N=319
DES
N=107
BMS
N=102
NICE Stent
NICE x stent 
interaction*
Age (years) 59.65±11.49 59.25±11.76 59.55±11.57 60.64±11.89 65.79±10.69 61.53±12.14 <0.001 0.64 0.016
Male gender, n (%) 120 (81.08) 124 (77.02) 266 (83.13) 254 (79.62) 77 (71.96) 77 (75.49) 0.24 0.33 0.50
Body mass index (kg/m²) 26.84±3.97 27.34±4.07 27.30±4.38 26.88±3.72 27.73±5.22 27.88±4.79 0.09 0.78 0.28
Cardiovascular risk factors
Diabetes mellitus, n (%) 0 (0.00) 0 (0.00) 22 (6.88) 26 (8.15) 62 (57.94) 64 (62.75) <0.001 0.68 0.97
Hypertension, n (%) 61 (41.22) 63 (39.13) 145 (45.31) 136 (42.63) 73 (68.22) 66 (64.71) <0.001 0.31 0.98
Hypercholesterolaemia, n (%) 68 (45.95) 82 (51.57) 189 (59.62) 184 (58.04) 67 (62.62) 62 (60.78) 0.002 0.97 0.55
Current smoker, n (%) 80 (54.79) 87 (54.37) 147 (46.37) 163 (51.42) 45 (42.86) 51 (51.52) 0.08 0.14 0.58
Family history of coronary artery disease, 
n (%) 52 (35.86) 48 (30.77) 107 (33.97) 101 (31.86) 34 (32.69) 30 (30.30) 0.71 0.29 0.90
Previous myocardial infarction, n (%) 4 (2.70) 4 (2.48) 22 (6.88) 18 (5.64) 5 (4.67) 10 (9.80) 0.02 0.94 0.30
Previous PCl, n (%) 2 (1.35) 3 (1.86) 10 (3.13) 16 (5.02) 7 (6.54) 8 (7.84) 0.002 0.25 0.91
Previous CABG, n (%) 1 (0.68) 0 (0.00) 6 (1.88) 4 (1.25) 3 (2.80) 0 (0.00) 0.20 0.11
Clinical presentation
Primary PCI (<12 hrs), n (%) 138 (93.24) 144 (89.44) 294 (91.88) 286 (89.66) 98 (91.59) 91 (89.22) 0.74 0.12 0.90
Killip class II, III or IV, n (%) 8 (5.41) 7 (4.35) 25 (7.81) 21 (6.58) 7 (6.54) 9 (8.82) 0.17 0.68 0.67
Left ventricular ejection fraction (%) 48.25±10.53 50.51±10.03 49.08±10.69 49.23±10.25 48.93±10.69 50.12±9.98 0.88 0.15 0.36
Site of infarct-related artery, n (%) 0.64 0.90 0.92
Left main (LM) 1 (0.68) 0 (0.00) 1 (0.31) 1 (0.31) 0 (0.00) 0 (0.00)
Left anterior descending (LAD) 68 (45.95) 70 (43.75) 113 (35.31) 113 (35.42) 45 (42.06) 47 (46.08)
Left circumflex (LCX) 21 (14.19) 25 (15.63) 45 (14.06) 51 (15.99) 16 (14.95) 14 (13.73)
Right circumflex (RCA) 58 (39.19) 65 (40.63) 161 (50.31) 153 (47.96) 45 (42.06) 41 (40.20)
Saphenous vein graft 0 (0.00) 0 (0.00) 0 (0.00) 1 (0.31) 1 (0.93) 0 (0.00)
Angiographic and procedural characteristics
TIMI flow 0 to 2 before PCI, n (%) 117 (79.59) 131 (82.91) 289 (90.31) 270 (84.64) 97 (90.65) 92 (90.20) 0.002 0.22 0.14
Thrombus aspiration, n (%) 97 (65.54) 120 (75.00) 189 (59.06) 202 (63.32) 64 (59.81) 52 (50.98) <0.001 0.22 0.09
Multivessel treatment, n (%) 2 (1.35) 1 (0.63) 26 (8.13) 25 (7.84) 4 (3.74) 9 (8.82) 0.003 0.74 0.29
Treatment of LAD, n (%) 69 (46.62) 71 (44.38) 123 (38.44) 120 (37.62) 46 (42.99) 48 (47.06) 0.64 0.93 0.76
Lesions and stenting
No. of lesions treated 1.01±0.08 1.00±0.00 1.21±0.50 1.25±0.55 1.18±0.43 1.23±0.46 <0.001 0.29 0.67
Total stent length (mm) 16.03±3.06 15.70±3.48 32.46±14.93 32.06±16.84 33.95±13.69 35.54±16.49 <0.001 0.71 0.64
Maximum stent diameter (mm) 3.37±0.34 3.51±2.00 3.29±0.48 3.31±0.73 3.00±0.49 3.01±0.48 <0.001 0.33 0.62
No. of stents implanted 0.99±0.08 0.99±0.16 1.67±0.78 1.66±0.98 1.68±0.81 1.76±0.91 <0.001 0.86 0.71
Direct stenting, n (%) 64 (43.54) 76 (48.41) 140 (43.75) 131 (41.07) 31 (28.97) 22 (21.57) <0.001 0.65 0.30
Overlapping stents, n (%) 0 (0.00) 1 (0.64) 111 (34.69) 86 (26.96) 38 (35.51) 34 (33.66) <0.001 0.046 0.41
Depicted are counts (%) or means±SD, p-values from ANOVAs or logistic regressions (NICE group linear, randomised stent). *p-value interaction NICE risk group (linear) x stent from the 
full-factorial models. Implanted stents criteria (identical Tu et al, 200730, except maximum diameter used): small vessel diameter: <3.0 mm  maximum diameter of stents implanted; large 
vessel diameter: ≥3.0 mm  maximum diameter of stents implanted. Long lesion length: ≥20 mm  total stent length implanted; short lesion length: <20 mm  total stent length 
implanted.
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Online Table 2. Baseline and procedural characteristics of EXAMINATION patients.
NICE risk factors
None One Two or three p-values
DES
N=176
BMS
N=189
DES
N=410
BMS
N=390
DES
N=165
BMS
N=168
NICE Stent
NICE x stent 
interaction*
Age (years) 57.73±11.38 58.50±12.64 61.14±12.43 61.93±12.47 63.19±11.92 64.38±12.01 <0.001 0.20 0.97
Male gender, n (%) 150 (85.23) 160 (84.66) 353 (86.10) 314 (80.51) 131 (79.39) 136 (80.95) 0.10 0.15 0.27
Body mass index (kg/m²) 27.27±3.62 27.46±4.02 27.31±3.76 27.20±3.91 27.08±4.00 27.96±3.59 0.58 0.36 0.16
Cardiovascular risk factors
Diabetes mellitus, n (%) 0 (0.00) 0 (0.00) 38 (9.27) 35 (8.97) 99 (60.37) 86 (51.19) <0.001 0.29 0.31
Hypertension, n (%) 72 (40.91) 84 (44.44) 181 (44.15) 194 (49.74) 94 (57.32) 100 (59.52) <0.001 0.09 0.87
Hypercholesterolaemia , n (%) 87 (49.43) 77 (40.74) 180 (43.90) 146 (37.44) 87 (53.05) 78 (46.43) 0.238 0.01 0.94
Current smoker, n (%) 94 (53.41) 110 (58.20) 202 (49.27) 203 (52.05) 76 (46.34) 73 (43.45) 0.004 0.42 0.57
Family history of coronary artery 
disease, n (%) 37 (22.29) 25 (14.20) 67 (17.36) 62 (17.27) 30 (20.00) 32 (20.78) 0.48 0.38 0.23
Previous myocardial infarction, n (%) 7 (3.98) 10 (5.29) 18 (4.39) 26 (6.67) 8 (4.88) 11 (6.55) 0.53 0.11 0.96
Previous PCl, n (%) 7 (3.98) 5 (2.65) 16 (3.90) 20 (5.13) 6 (3.66) 7 (4.17) 0.65 0.68 0.59
Previous CABG, n (%) 0 (0.00) 5 (2.65) 1 (0.24) 2 (0.51) 2 (1.22) 0 (0.00) 0.20 0.22
Clinical presentation
Primary PCI (<12 hrs), n (%) 146 (82.95) 155 (82.01) 351 (85.61) 339 (86.92) 133 (80.61) 144 (85.71) 0.75 0.41 0.56
Killip class II, III or IV, n (%) 14 (8.00) 17 (9.04) 42 (10.27) 43 (11.08) 24 (14.55) 16 (9.52) 0.13 0.77 0.34
Left ventricular ejection fraction (%) 52.94±11.47 50.08±9.15 51.00±10.84 51.40±9.99 49.49±11.42 51.17±9.60 0.46 0.86 0.04
Site of infarct-related artery, n (%) 0.72 0.71 0.71
Left main (LM) 0 (0.00) 1 (0.53) 1 (0.24) 1 (0.26) 0 (0.00) 0 (0.00)
Left anterior descending (LAD) 74 (42.05) 85 (44.97) 165 (40.24) 156 (40.00) 84 (50.91) 64 (38.10)
Left circumflex (LCX) 26 (14.77) 24 (12.70) 54 (13.17) 46 (11.79) 22 (13.33) 37 (22.02)
Right circumflex (RCA) 76 (43.18) 77 (40.74) 188 (45.85) 185 (47.44) 58 (35.15) 67 (39.88)
Saphenous vein graft 0 (0.00) 2 (1.06) 2 (0.49) 2 (0.51) 1 (0.61) 0 (0.00)
Angiographic and procedural characteristics
TIMI flow 0 to 2 before PCI, n (%) 128 (73.14) 151 (80.75) 335 (82.11) 318 (82.17) 123 (74.55) 137 (82.04) 0.63 0.10 0.25
Thrombus aspiration, n (%) 121 (68.75) 126 (66.67) 279 (68.05) 260 (66.67) 95 (57.58) 95 (56.55) 0.004 0.54 0.99
Multivessel treatment, n (%) 0 (0.00) 1 (0.53) 23 (5.61) 10 (2.56) 5 (3.03) 5 (2.98) 0.027 0.07 0.29
Treatment of LAD, n (%) 74 (42.05) 85 (44.97) 169 (41.22) 159 (40.77) 85 (51.52) 64 (38.10) 0.78 0.34 0.07
Lesions and stenting
No. of lesions treated 1.02±0.18 1.03±0.19 1.26±0.50 1.23±0.47 1.24±0.47 1.23±0.46 <0.001 0.43 0.88
Total stent length (mm) 16.44±2.05 16.37±2.19 31.04±15.17 29.54±13.58 32.62±15.17 32.89±12.68 <0.001 0.20 0.46
Maximum stent diameter (mm) 3.36±0.34 3.34±0.34 3.27±0.42 3.25±0.44 2.94±0.50 2.89±0.46 <0.001 0.22 0.86
No. of stents implanted 1.00±0.00 1.00±0.00 1.50±0.70 1.45±0.67 1.55±0.74 1.63±0.72 <0.001 0.66 0.26
Direct stenting, n (%) 132 (76.74) 141 (79.66) 240 (59.70) 224 (58.03) 79 (47.88) 69 (41.32) <0.001 0.54 0.44
Overlapping stents, n (%) 0 (0.00) 0 (0.00) 136 (33.17) 125 (32.05) 62 (37.58) 81 (48.21) <0.001 0.60 0.07
Depicted are counts (%) or means±SD, p-values from ANOVAs or logistic regressions (NICE group linear, randomised stent). *p-value interaction NICE risk group (linear) x stent from the 
full-factorial models. Implanted stents criteria (identical Tu et al, 200730, except maximum diameter used): small vessel diameter: <3.0 mm  maximum diameter of stents implanted; large 
vessel diameter: ≥3.0 mm  maximum diameter of stents implanted. Long lesion length: ≥20 mm  total stent length implanted; short lesion length: <20 mm  total stent length 
implanted.
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Selective use of DES in primary angioplasty
Online Table 3. Medication use at procedure, discharge and follow-up of COMFORTABLE patients.
NICE risk factors
None One Two or three p-values
DES
N=148
BMS
N=161
DES
N=320
BMS
N=319
DES
N=107
BMS
N=102
NICE Stent
NICE x stent 
interaction
During primary PCI
Aspirin*, n (%) 147 (100.00) 161 (100.00) 317 (99.06) 315 (99.06) 107 (100.00) 101 (99.02) 0.36 0.72
Clopidogrel*, n (%) 124 (84.35) 137 (85.09) 257 (80.31) 253 (79.31) 90 (84.11) 81 (79.41) 0.29 0.62 0.73
Prasugrel*, n (%) 53 (36.05) 52 (32.30) 140 (43.75) 141 (44.20) 38 (35.51) 45 (44.12) 0.10 0.82 0.36
Any DAPT*, n (%) 146 (99.32) 161 (100.00) 317 (99.06) 315 (98.75) 107 (100.00) 99 (97.06) 0.18 0.38
Unfractionated heparin, n (%) 137 (92.57) 144 (89.44) 279 (87.19) 288 (90.28) 94 (87.85) 91 (89.22) 0.34 0.52 0.34
Low molecular weight heparin, n (%) 8 (5.41) 3 (1.86) 7 (2.19) 12 (3.76) 4 (3.74) 4 (3.92) 0.94 0.97 0.14
Bivalirudin, n (%) 12 (8.11) 19 (11.80) 49 (15.31) 37 (11.60) 13 (12.15) 11 (10.78) 0.48 0.48 0.27
Glycoprotein IIb/IIIa antagonists, n (%) 81 (54.73) 78 (48.45) 149 (46.56) 146 (45.77) 46 (42.99) 42 (41.18) 0.032 0.43 0.73
At discharge
Aspirin, n (%) 148 (100.00) 159 (98.76) 315 (99.68) 316 (100.00) 105 (100.00) 101 (100.00) 0.16 0.58
Any DAPT, n (%) 148 (100.00) 157 (97.52) 314 (99.37) 316 (100.00) 105 (100.00) 101 (100.00) 0.05 0.43
At 30 days
Aspirin, n (%) 147 (100.00) 156 (97.50) 309 (99.04) 309 (99.68) 100 (99.01) 100 (100.00) 0.28 0.76
Any DAPT, n (%) 147 (100.00) 153 (95.63) 308 (98.72) 307 (99.03) 99 (98.02) 99 (99.00) 0.38 0.24 0.78
At one year
Aspirin, n (%) 138 (98.57) 146 (95.42) 297 (98.02) 288 (96.64) 94 (94.95) 90 (96.77) 0.58 0.22 0.30
Any DAPT, n (%) 129 (92.14) 128 (83.66) 274 (90.43) 269 (90.27) 85 (85.86) 81 (87.10) 0.87 0.25 0.16
Depicted are counts (%) or means±SD, p-values from ANOVAs or logistic regressions (NICE group linear, randomised stent). DAPT was ASA with clopidogrel or prasugrel in COMFORTABLE. 
*Loading dosage or already on daily dosage for ASA, clopidogrel and prasugrel. Implanted stents criteria (identical Tu et al, 200730, except maximum diameter used): small vessel diameter: 
<3.0 mm  maximum diameter of stents implanted; large vessel diameter: ≥3.0 mm  maximum diameter of stents implanted. Long lesion length: ≥20 mm  total stent length 
implanted; short lesion length: <20 mm  total stent length implanted. DAPT: dual antiplatelet therapy
Online Table 4. Medication use at procedure, discharge and follow-up of EXAMINATION patients.
NICE risk factors
None One Two or three p-values
DES BMS DES BMS DES BMS
NICE Stent
NICE x stent 
interactionN=176 N=189 N=410 N=390 N=165 N=168
During primary PCI
Aspirin*, n (%) 164 (93.18) 174 (92.06) 375 (91.46) 357 (91.54) 155 (93.94) 163 (97.02) 0.16 0.71 0.40
Clopidogrel*, n (%) 167 (94.89) 172 (91.01) 391 (95.37) 371 (95.13) 154 (93.33) 163 (97.02) 0.16 0.80 0.11
Any DAPT*, n (%) 161 (91.48) 165 (87.30) 370 (90.24) 350 (89.74) 148 (89.70) 160 (95.24) 0.16 0.97 0.07
Unfractionated heparin, n (%) 145 (82.39) 154 (81.48) 328 (80.00) 308 (78.97) 126 (76.36) 128 (76.19) 0.07 0.71 0.98
Low molecular weight heparin, n (%) 13 (7.39) 17 (8.99) 33 (8.05) 33 (8.46) 16 (9.70) 21 (12.50) 0.19 0.40 0.85
Bivalirudin, n (%) 16 (9.09) 13 (6.88) 21 (5.12) 31 (7.95) 12 (7.27) 12 (7.14) 0.68 0.46 0.26
Glycoprotein IIb/IIIa antagonists, n (%) 73 (41.48) 78 (41.27) 160 (39.02) 146 (37.44) 57 (34.55) 55 (32.74) 0.036 0.61 0.97
At discharge
Aspirin, n (%) 175 (100.00) 186 (100.00) 404 (98.78) 385 (99.23) 162 (99.39) 166 (98.81) 0.16 0.77 0.43
Any DAPT, n (%) 175 (100.00) 186 (100.00) 404 (98.78) 384 (99.22) 160 (98.77) 166 (98.81) 0.08 0.57 0.73
At 30 days
Aspirin, n (%) 160 (99.38) 171 (99.42) 370 (98.14) 357 (98.89) 144 (97.96) 154 (99.35) 0.39 0.23 0.82
Any DAPT, n (%) 160 (99.38) 171 (99.42) 367 (97.09) 353 (98.06) 142 (96.60) 154 (99.35) 0.18 0.12 0.53
At one year
Aspirin, n (%) 145 (97.32) 168 (99.41) 370 (97.63) 342 (98.56) 143 (97.28) 151 (96.79) 0.23 0.26 0.42
Any DAPT, n (%) 142 (94.67) 154 (91.12) 366 (96.57) 304 (87.61) 142 (96.60) 137 (87.82) 0.74 <0.001 0.29
Depicted are counts (%) or means ± SD, p-values from ANOVAs or logistic regressions (NICE group linear, randomised stent). DAPT was ASA with clopidogrel in EXAMINATION. *Loading dosage 
or already on daily dosage for ASA and clopidogrel. Implanted stents criteria (identical Tu et al, 200730, except maximum diameter used): small vessel diameter: <3.0 mm  maximum 
diameter of stents implanted; large vessel diameter: ≥3.0 mm  maximum diameter of stents implanted. Long lesion length: ≥20 mm  total stent length implanted; short lesion length: 
<20 mm  total stent length implanted. DAPT: dual antiplatelet therapy
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Outcome Risk score Patients in Risk ratio p-value Interactiona
DES/BMS group (95% Cl)
MACE
Two or three 272/270 0.786 (0.466-1.323) 0.365
0.317
One 730/709 0.583 (0.391-0.871) 0.008
None 324/350 0.224 (0.016-3.165) 0.268
tau2
0.00
0.00
2.71
I2
0.00
0.00
69.99
Death
Two or three 272/270 1.833 (0.614-5.471) 0.365
0.171
One 730/709 0.730 (0.417-1.275) 0.008
None 324/350 0.513 (0.112-2.341) 0.268
0.27
0.00
0.57
43.44
0.00
42.89
Reinfarction
Two or three 272/270 0.593 (0.235-1.498) 0.365
0.987
One 730/709 0.599 (0.283-1.267) 0.008
None 324/350 0.583 (0.136-2.495) 0.268
0.00
0.00
0.00
0.00
0.00
0.00
TLR (clinically indicated) 
Two or three 272/270 0.295 (0.129-0.678) 0.365
0.890
One 730/709 0.444 (0.237-0.831) 0.008
None 324/350 0.130 (0.024-0.709) 0.268
0.00
0.00
0.00
0.00
0.00
0.00
Definite stent thrombosis 
Two or three 272/270 0.487 (0.124-1.921) 0.304
0.799
One 730/709 0.361 (0.085-1.539) 0.168
None 324/350 0.378 (0.042-3.401) 0.385
0.00
0.51
0.42
0.00
46.95
16.67
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Online Figure 1. Pooled analysis of clinical endpoints according to stent used in the three risk score groups. p-values random effects using 
separate meta-analyses per outcome and risk score. a p-values from test for trend over NICE risk factors using separate meta-regressions per 
outcome.
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Outcome Events Events Risk ratio I2 p-valuea p-value
DES BMS (95% Cl) interactionb
MACE
Diabetes - yes 21/221 21/211 0.96 (0.54-1.70) 0 0.875 0.029
Diabetes - no 44/1,105 90/1,118 0.50 (0.35-0.71) 0 <0.001
Small vessel - yes 12/248 25/265 0.54 (0.24-1.22) 30 0.138 0.425
Small vessel - no 53/1,078 86/1,064 0.59 (0.34-1.03) 62 0.064
Long lesion - yes 51/834 74/800 0.66 (0.47-0.93) 0 0.018 0.154
Long lesion - no 14/492 37/529 0.35 (0.11-1.13) 56 0.080
Death
Diabetes - yes 17/221 10/211 1.63 (0.75-3.51) 0 0.216 0.035
Diabetes - no 27/1,105 39/1,118 0.70 (0.43-1.14) 0 0.150
Small vessel - yes 7/248 6/265 1.23 (0.42-3.62) 0 0.706 0.266
Small vessel - no 37/1,078 43/1,064 0.85 (0.55-1.31) 0 0.458
Long lesion - yes 33/834 31/800 1.02 (0.63-1.65) 0 0.934 0.175
Long lesion - no 11/492 18/529 0.67 (0.31-1.41) 0 0.289
Reinfarction
Diabetes - yes 5/221 10/211 0.50 (0.17-1.44) 0 0.197 0.359
Diabetes - no 16/1,105 26/1,118 0.62 (0.34-1.16) 0 0.138
Small vessel - yes 4/248 9/265 0.48 (0.15-1.56) 0 0.221 0.345
Small vessel - no 17/1,078 27/1,064 0.63 (0.34-1.15) 0 0.131
Long lesion - yes 16/834 25/800 0.61 (0.33-1.14) 0 0.120 0.399
Long lesion - no 5/492 11/529 0.52 (0.18-1.53) 0 0.236
TLR
Diabetes - yes 5/221 14/211 0.36 (0.13-0.99) 0 0.048 0.426
Diabetes - no 17/1,105 54/1,118 0.32 (0.19-0.55) 0 <0.001
Small vessel - yes 5/248 19/265 0.30 (0.10-0.88) 12 0.028 0.419
Small vessel - no 17/1,078 49/1,064 0.35 (0.18-0.67) 29 0.002
Long lesion - yes 18/834 48/800 0.36 (0.21-0.61) 0 0.000 0.309
Long lesion - no 4/492 20/529 0.25 (0.06-0.98) 20 0.047
Definite stent thrombosis
Diabetes - yes 3/221 4/211 0.76 (0.15-3.88) 0 0.737 0.167
Diabetes - no 6/1,105 22/1,118 0.29 (0.11-0.81) 17 0.018
Small vessel - yes 1/248 4/265 0.37 (0.06-2.38) 0 0.293 0.494
Small vessel - no 8/1,078 22/1,064 0.36 (0.16-0.81) 0 0.013
Long lesion - yes 7/834 19/800 0.36 (0.09-1.49) 57 0.158 0.462
Long lesion - no 2/492 7/529 0.41 (0.04-4.26) 47 0.456
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Online Figure 2. Meta-analysis of clinical outcomes in presence of individual risk factors (lesion length, vessel size and diabetes) for DES vs. 
BMS use. a p-values random effects using separate meta-analyses per outcome and per presence or absence of the risk factor; bp-values from 
a Z-test for the interaction between stent type and presence/absence of risk factor
